Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.15+0.30 (+1.16%)
Close on Nov 13, 2026Market cap $1.25BP/E –Yield –
Rapport Therapeutics cash
Cash and short-term investments held at the end of each period.
Rapport Therapeutics's cash was $395.00M at Sep 30, 2026. For fiscal 2025 it was $490.50M, up 60.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $490.50M | +60.7% |
| FY2024 | Dec 31, 2024 | $305.30M | +107.0% |
| FY2023 | Dec 31, 2023 | $147.48M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $395.00M | -23.0% |
| Q2 FY2026 | Jun 30, 2026 | $436.08M | +67.5% |
| Q1 FY2026 | Mar 31, 2026 | $476.80M | +67.1% |
| Q4 FY2025 | Dec 31, 2025 | $490.50M | +60.7% |
| Q3 FY2025 | Sep 30, 2025 | $513.00M | +60.0% |
| Q2 FY2025 | Jun 30, 2025 | $260.40M | -22.5% |
| Q1 FY2025 | Mar 31, 2025 | $285.40M | +284.3% |
| Q4 FY2024 | Dec 31, 2024 | $305.30M | +107.0% |
| Q3 FY2024 | Sep 30, 2024 | $320.70M | +101.2% |
| Q2 FY2024 | Jun 30, 2024 | $336.10M | +322.6% |
| Q1 FY2024 | Mar 31, 2024 | $74.27M | – |
| Q4 FY2023 | Dec 31, 2023 | $147.48M | – |
| Q3 FY2023 | Sep 30, 2023 | $159.41M | – |
| Q2 FY2023 | Jun 30, 2023 | $79.53M | – |
See a number that looks wrong?